Eli Lilly and Company (LLY)vsOmada Health, Inc. Common Stock (OMDA)
LLY
Eli Lilly and Company
$1,152.70
-1.64%
HEALTHCARE · Cap: $994.92B
OMDA
Omada Health, Inc. Common Stock
$20.69
-3.18%
HEALTHCARE · Cap: $1.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 25619% more annual revenue ($79.67B vs $309.76M). LLY leads profitability with a 33.5% profit margin vs 1.4%. OMDA trades at a lower P/E of 31.0x. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
OMDA
Hold37
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Revenue surging 43.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.3x book value
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
1.4% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : OMDA
The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 43.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : OMDA
The primary concerns for OMDA are P/E Ratio, EPS Growth, Market Cap. Thin 1.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while OMDA is a hypergrowth play — different risk/reward profiles.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 37/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Omada Health, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?